ARROWHEAD PHARMACEUTICALS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 177 E COLORADO BLVD, PASADENA, CA, 91105
Mailing Address 177 E COLORADO BLVD, PASADENA, CA, 91105
Phone 626-696-4702
Fiscal Year End 0930
EIN 460408024
Financial Overview
FY2025
$1.14B
Total Assets
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 5, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 5, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | January 27, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 21, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 9, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 9, 2026 | View on SEC |
Annual Reports
10-K November 25, 2025
- Completed and reclassified a major construction project into a new manufacturing facility, enhancing production capabilities.
- Established a new license agreement with Sanofi in August 2025, expanding collaboration avenues.
Insider Trading
STRONG SELL 8 insiders
56 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.